CA2494155A1 - Arginine silicate inositol complex and use thereof - Google Patents

Arginine silicate inositol complex and use thereof Download PDF

Info

Publication number
CA2494155A1
CA2494155A1 CA002494155A CA2494155A CA2494155A1 CA 2494155 A1 CA2494155 A1 CA 2494155A1 CA 002494155 A CA002494155 A CA 002494155A CA 2494155 A CA2494155 A CA 2494155A CA 2494155 A1 CA2494155 A1 CA 2494155A1
Authority
CA
Canada
Prior art keywords
effective amount
medicament
arginine silicate
manufacture
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002494155A
Other languages
French (fr)
Other versions
CA2494155C (en
Inventor
Vijaya Juturu
James R. Komorowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrition 21 LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2733212A priority Critical patent/CA2733212C/en
Publication of CA2494155A1 publication Critical patent/CA2494155A1/en
Application granted granted Critical
Publication of CA2494155C publication Critical patent/CA2494155C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A method for preventing and treating a variety of disease states and disorde rs is provided, comprising the administration of an arginine silicate inositol complex to an individual in the presence of medical therapy or absence of medical therapy. Examples of said disease states and disorders include bone and cartilage disorders and cardiovascular disease and its associated micro and macro vascular complications including infections and inflammation of al l these diseases in combination or without. Advantageously, the amount of arginine silicate inositol complex administered per day is between about 2 mg/Kg body weight to 2,500 mg/Kg body weight or from a low dose to a higher dose to observe normal metabolic functions and healthy and the delivery is parenteral, oral or intravenous or topical by solid or liquid or both.</SDOA B>

Claims (34)

1. Use of a composition comprising an effective amount of arginine silicate inositol complex for the manufacture of a medicament for ameliorating the symptoms of a bone or cartilage disorder in an individual at risk thereof.
2. The use of Claim 1, wherein said arginine silicate inositol is administered in a form selected from the group consisting of a powder, a liquid, and a combination of a powder and a liquid.
3. The use of Claim 1, wherein said bone disorder is selected from the group consisting of osteoporosis, osteogenesis imperfect, and bone fractures.
4. The use of Claim 1, wherein said cartilage disorder is selected from the group consisting of osteoarthritis, inflammatory arthritis, a torn tendon, and a torn ligament.
5. The use of Claim 1, wherein said administration is accomplished parenterally, orally, or intravenously.
6. The use of Claim 1, wherein arginine-silicate-inositol is administered in conjunction with other conventional bone therapies.
7. The use of Claim 6, wherein said other bone therapies are selected from the group consisting of surgery, casting, calcium supplementation and anti-bone resorption drugs.
8. The use of Claim 1, wherein said effective amount of said arginine silicate inositol complex comprises arginine, silicate, and inositol at a molar ratio selected from the group consisting of between about 2:2:1 2:2:1; 2: 2:1.5; 1: 1: 1; 2: 2:3; and 3:3:2.
9. Use of a composition comprising an effective amount of an arginine silicate inositol complex for the manufacture of a medicament for increasing levels of collagen in an individual.
10. The use of Claim 9, wherein said arginine silicate inositol complex is administered parenterally, orally, intravenously, or topically.
11. Use of a composition comprising an effective amount of an arginine silicate inositol complex for the manufacture of a medicament for increasing bone length in an individual.
12. The use of claim 11, wherein said increase is in femur length.
13. Use of a composition comprising an effective amount of an arginine silicate inositol complex for the manufacture of a medicament for reversing the weakening of bone due to a reduction in mechanical stress.
14. The use of Claim 13, wherein the cause of the reduction of mechanical stress is selected from the group consisting of exposure to weightlessness and immobilization.
15. Use of a composition comprising an effective amount of arginine silicate inositol complex for the manufacture of a medicament for decreasing insulin resistance in an individual.
16. Use of a composition comprising an effective amount of arginine silicate inositol for the manufacture of a medicament for treating a disease secondary to coronary vascular disease.
17. The use of Claim 16, wherein said diseases is selected from the group consisting of nephrosclerosis, abnormal liver lipid concentrations, microvascular complications, and macrovascular complications.
18. Use of a composition comprising an effective amount of arginine silicate inositol for the manufacture of a medicament for stabilizing hormone levels to improve metabolic function in an individual in need thereof.
19. Use of a composition comprising an effective amount of an arginine silicate inositol complex for the manufacture of a medicament for increasing nitric oxide production in an individual in need thereof.
20. Use of a composition comprising an effective amount of an arginine silicate inositol complex for the manufacture of a medicament for treating a disorder caused by or exacerbated by reduced levels of nitric oxide.
21. The use of Claim 20, wherein said disorder is selected from the group consisting of pulmonary hypertension, renal disease, atherosclerosis, hypertension, diabetes, hypercholesterolemia, hyperglycemia, heart failure, Fabry's disease, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, Crohn's disease, ulcerative colitis, perinatal asphyxia, meconium aspiration syndrome, Group B strep sepsis, congenital diaphragmatic hernia, ischemic heart disease, hyperhomocysteinemia, multiple sclerosis, Takayasu's arteritis, autosomal dominant polycystic kidney disease, end-stage renal failure, cancer and liver disease.
22. The use of claim 20, wherein said medicament is for coadministration with a second beneficial agent effective in treating disorders caused by or exacerbated by reduced levels of NO, wherein said second beneficial agent is a conventional therapy for NO
deficiencies.
23. Use of a composition comprising an effective amount of an arginine silicate inositol complex for the manufacture of a medicament for reducing the concentration of a marker for bone resorption in the tissue of an individual.
24. The use of claim 23, wherein said marker of bone resorption is selected from the group consisting of pyridinoline cross-linking peptides, including C- and N-telopeptides, N-telopeptide cross-links (NTx), C-telopeptide cross links (CTx) and pyridinoline cross-linked carboxyterminal peptides (ICTP), total, peptide-bound and free pyridinoline, hydroxyproline, deoxypyridinoline, tartrate-resistant acid phosphatase and bone sialoprotein.
25. Use of a composition comprising an effective amount of an arginine silicate inositol complex for the manufacture of a medicament for increasing the concentration of a marker for bone formation in the tissue of an individual.
26. The use of claim 25, wherein said marker of bone formation is selected from the group consisting of osteocalcin, alkaline phosphatase and procollagen type I C-/N-extension peptides (PICP, PINP).
27. Use of a composition comprising an effective amount of an arginine silicate inositol complex for the manufacture of a medicament for reducing markers of poor cardiovascular health.
28. The use of claim 27, wherein said marker of poor cardiovascular health is selected from the group consisting of elevated urinary albumin concentration and increased vascular contractility.
29. Use of a composition comprising an effective amount of an arginine silicate inositol complex for the manufacture of a medicament for promoting cardiovascular health in an individual in need thereof.
30. The use of Claim 1, 9, 11, 13, 15, 16, 18, 19, 20, 23, 25, 27 or 29, wherein the medicament contains from about 2 to about 2,500 mg of said arginine silicate inositol complex.
31. The use of Claim 1, 9, 11, 13, 15, 16, 18, 19, 20, 23, 25, 27 or 29 wherein said effective amount of said arginine silicate complex is between about 2 mg/kg body weight and about 2,500 mg/Kg body weight.
32. The use of Claim 31, wherein said effective amount of said arginine silicate complex is between about 5mg/Kg body weight and about 1,000 mg/Kg body weight.
33. The use of Claim 1, 9, 11, 13, 15, 16, 18, 19, 20, 23, 25, 27 or 29, wherein said individual is a mammal.
34. The use of Claim 11, 13, 15, 16, 18, 19, 20, 23, 25, 27 or 29, wherein said arginine silicate inositol complex is administered orally, intravenously, or parenterally.
CA2494155A 2002-08-22 2003-08-22 Arginine silicate inositol complex and use thereof Expired - Lifetime CA2494155C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2733212A CA2733212C (en) 2002-08-22 2003-08-22 Arginine silicate inositol complex and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40574902P 2002-08-22 2002-08-22
US60/405,749 2002-08-22
PCT/US2003/026370 WO2004017913A2 (en) 2002-08-22 2003-08-22 Arginine silicate inositol complex and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2733212A Division CA2733212C (en) 2002-08-22 2003-08-22 Arginine silicate inositol complex and use thereof

Publications (2)

Publication Number Publication Date
CA2494155A1 true CA2494155A1 (en) 2004-03-04
CA2494155C CA2494155C (en) 2011-05-03

Family

ID=31946926

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2733212A Expired - Lifetime CA2733212C (en) 2002-08-22 2003-08-22 Arginine silicate inositol complex and use thereof
CA2494155A Expired - Lifetime CA2494155C (en) 2002-08-22 2003-08-22 Arginine silicate inositol complex and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2733212A Expired - Lifetime CA2733212C (en) 2002-08-22 2003-08-22 Arginine silicate inositol complex and use thereof

Country Status (7)

Country Link
US (2) US20040097467A1 (en)
EP (1) EP1534302A4 (en)
JP (1) JP2006501224A (en)
AU (1) AU2003262804A1 (en)
CA (2) CA2733212C (en)
MX (1) MXPA05001928A (en)
WO (1) WO2004017913A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049599A1 (en) * 2003-10-31 2007-03-01 Altana Pharma Ag Use of bh4 for the treatment of respiratory diseases
AU2005271242B9 (en) * 2004-08-12 2012-04-12 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions for controlled release delivery of biologically active compounds
GB0504657D0 (en) * 2005-03-05 2005-04-13 Psimedica Ltd Compositions and methods of treatment
JP2009523176A (en) * 2006-01-11 2009-06-18 スミスクライン・ビーチャム・コーポレイション New compounds
US11246638B2 (en) 2006-05-03 2022-02-15 P Tech, Llc Methods and devices for utilizing bondable materials
ES2652114T3 (en) 2007-10-15 2018-01-31 7 Oaks Pharmaceutical Corporation A solution containing silicate for use in the treatment of melanoma
WO2010028211A1 (en) * 2008-09-04 2010-03-11 Rozmanith Anthony I Health care
CA2805961A1 (en) * 2010-07-21 2012-01-26 Oleg Iliich Epshtein Pharmaceutical composition comprising homeopathically potentized antibodies to human insulin receptor and endothelial no synthase
WO2012035364A1 (en) 2010-09-15 2012-03-22 Creogen D.O.O. Stabilized solution of ortho-silicic acid, its preparation and use
GB201402672D0 (en) 2014-02-14 2014-04-02 Medical Res Council Materials and methods relating to stabilised polymeric silicate compositions
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US10155009B2 (en) 2015-04-16 2018-12-18 General Incorporated Association Tsukuba Global Innovation Promotion Agency Polyion complex of poly(L-arginine) segment-containing block copolymer and polyanionic polymer
EP3316876B1 (en) * 2015-06-30 2020-03-11 Nutrition 21, LLC Arginine silicate inositol for improving cognitive function
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
MX2019002468A (en) 2016-09-01 2019-09-18 Jds Therapeutics Llc Magnesium biotinate compositions and methods of use.
WO2018064469A1 (en) 2016-09-29 2018-04-05 K.L.R.M., Llc Compositions and methods for the treatment of orthopedic ailments
WO2020092431A1 (en) * 2018-11-02 2020-05-07 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
GB2613672A (en) 2019-12-16 2023-06-14 Nutrition 21 Llc Methods of production of aginine-silicate complexes
WO2023086283A1 (en) * 2021-11-12 2023-05-19 Lonza Greenwood Llc Method for treating skeletal articulations and composition and uses thereof
WO2023086567A1 (en) * 2021-11-12 2023-05-19 Nutrition21, LLC Compositions and methods for treating or preventing myopathy in poultry

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337403A (en) * 1963-09-05 1967-08-22 Hoffmann La Roche Stable and palatable pharmaceutical compositions
US4297349A (en) * 1980-04-15 1981-10-27 Sandoz, Inc. Silicon-bearing carboxylic acids and amides
US4385052A (en) * 1981-07-20 1983-05-24 International Plant Research Institute, Inc. Use of trialkylsilyl-6-aminonicotinamides for the treatment of psoriasis
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
FR2610522B1 (en) 1987-02-06 1989-08-18 Gueyne Jean THERAPEUTIC PRODUCT BASED ON ORGANIC SILICON DERIVATIVES
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
US5132394A (en) * 1989-08-14 1992-07-21 Amoco Corporation Fiber-reinforced composites comprising amide-imide copolymer matrix resin
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5250569A (en) * 1991-04-22 1993-10-05 Godfrey Science & Design, Inc. Amino acid flavorings of aluminum astringent for oral use
US5679337A (en) * 1991-06-14 1997-10-21 Professional Pharmaceutical, Inc. Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient
CA2103163C (en) * 1991-08-26 1998-10-20 Mou-Ying Fu Lu Compositions and methods for the sublingual or buccal administration of therapeutic agents
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
TW282398B (en) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
ATE299892T1 (en) * 1994-05-18 2005-08-15 Nektar Therapeutics METHODS AND COMPOSITIONS FOR DRY POWDER MEDICATION FROM INTERFERONS
FI95441C (en) * 1994-05-31 1996-02-12 Leiras Oy Inhaler drug chamber
US5804203A (en) * 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5763496A (en) * 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
ES2148812T3 (en) * 1995-12-07 2000-10-16 Jago Res Ag INHALER FOR THE ADMINISTRATION OF MULTIPLE DOSE OF A DRY PHARMACOLOGICAL POWDER.
FR2745498A1 (en) * 1996-02-29 1997-09-05 Giroux Jean Marc Composition to treat obesity, improves renal tolerance and rate of weight loss
US5871010A (en) * 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
GB9626233D0 (en) * 1996-12-18 1997-02-05 Chawla Brinda P S Medicament packaging and deliveery device
US5707970A (en) * 1997-02-12 1998-01-13 Nutrition 21 Arginine silicate complex and use thereof
US20020068365A1 (en) * 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
US6143786A (en) * 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US6803456B1 (en) * 2003-08-13 2004-10-12 Rutherford Chemicals Llc Process for the production of arginine-silicate complex

Also Published As

Publication number Publication date
JP2006501224A (en) 2006-01-12
US20050234019A1 (en) 2005-10-20
CA2733212A1 (en) 2004-03-04
EP1534302A2 (en) 2005-06-01
CA2494155C (en) 2011-05-03
AU2003262804A1 (en) 2004-03-11
EP1534302A4 (en) 2009-01-07
WO2004017913A2 (en) 2004-03-04
US7576132B2 (en) 2009-08-18
CA2733212C (en) 2014-01-07
MXPA05001928A (en) 2005-08-29
AU2003262804A8 (en) 2004-03-11
WO2004017913A3 (en) 2004-10-28
US20040097467A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
CA2494155A1 (en) Arginine silicate inositol complex and use thereof
Grant et al. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases
Musso Magnesium metabolism in health and disease
US7078376B1 (en) Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
Pierson et al. A double-blind trial of corticosteroid therapy in status asthmaticus
CA2683628C (en) Method of treating vitamin d insufficiency and deficiency
JP3529790B2 (en) Use of Vitamin D lower 2 or Vitamin D lower 4 derivatives in the manufacture of a medicament for the treatment of secondary hyperparathyroidism
US10583168B1 (en) Nutritional supplements including cardiovascular support components
JP2006501224A5 (en)
AU1059601A (en) Pharmaceutical compositions and preparations for treatment of metabolic bone disease
Wisneski et al. Salmon calcitonin in hypercalcemia
JP2005505606A5 (en)
PT624374E (en) USES OF SULODEXIDA AND MEDICINES CONTAINING SUCH COMPOUND FOR THE TREATMENT OF DIABETIC NEFROPATHY
Carroll et al. Endocrine and metabolic emergencies: hypocalcaemia
JP3616116B2 (en) Pharmaceutical composition comprising L-carnitine or acyl-L-carnitine with an ACE inhibitor for the treatment of cardiovascular disorders
Weiner et al. Disorders of potassium metabolism
WO2019118952A1 (en) Veterinary supplement for effecting bone and cartilage
Rosenbloom Optimizing drug treatment of alcohol withdrawal
DE602004010172T2 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF KIDNEY FUNCTIONAL DISORDERS
JP2788340B2 (en) Inflammation treatment
US20080261866A1 (en) Compositions Comprising Glycosaminoglycan and Nonsteroidal Anti-Inflammatory Drug
Deshpande et al. Reflections of the Anesthetic Management in a Case of Parathyroid Adenoma: A Case Report
US7968600B2 (en) Medicament for preventive and therapeutic treatment of physical dysfunction caused by nerve damage
Grozeva et al. Calcium-Phosphate Metabolism Disorders in Patients with Renal Failure Clinical Significance, Diagnosis and Treatment
Jeffries et al. Life-threatening tertiary hyperparathyroidism in the critically ill

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230822